Oxanthrazole | CAS#118201-50-6 | antitumor

MedKoo Cat#: 584942 | Name: Oxanthrazole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxanthrazole has antitumor properties. Piroxantrone is one of a series of compounds commonly known as anthrapyrazoles developed in an effort to combine the broad antitumor activity of the anthracyclines with decreased myocardial toxicity.

Chemical Structure

Oxanthrazole

CAS#118201-50-6

Theoretical Analysis

MedKoo Cat#: 584942

Name: Oxanthrazole

CAS#: 118201-50-6

Chemical Formula: C21H26ClN5O4

Exact Mass: 447.1673

Molecular Weight: 447.92

Elemental Analysis: C, 56.31; H, 5.85; Cl, 7.91; N, 15.64; O, 14.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Oxanthrazole; NSC-349174

IUPAC/Chemical Name

Anthra(1,9-cd)pyrazol-6(2H)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-, hydrochloride

InChi Key

VPNCYQLYSZKURZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H25N5O4.ClH/c22-6-1-7-24-12-2-3-13-17-16(12)21(30)19-15(29)5-4-14(28)18(19)20(17)25-26(13)10-8-23-9-11-27;/h2-5,23-24,27-29H,1,6-11,22H2;1H

SMILES Code

O=C1C2=C3C(N(CCNCCO)N=C3C4=C1C(O)=CC=C4O)=CC=C2NCCCN.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 447.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Clark MP, Leaman DW, Hazelhurst LA, Hwang ES, Quinn A. An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2016 Feb;31:74-87. doi: 10.1016/j.intimp.2015.12.014. Epub 2015 Dec 18. PubMed PMID: 26709219. 2: Simpkins H, Figliomeni M, Rosen M. The interaction of platinum and anthrapyrazole antitumor drugs with mouse thymocytes studied by terbium fluorescence. Biochim Biophys Acta. 1988 Oct 28;972(1):25-32. PubMed PMID: 2846072. 3: Myers CE. Anthracyclines. Cancer Chemother Biol Response Modif. 1992;13:45-52. Review. PubMed PMID: 1389917. 4: Begleiter A, Lin D, Larson KK, Lang J, Wu X, Cabral T, Taylor H, Guziec LJ, Kerr PD, Hasinoff BB, Guziec FS Jr. Structure-activity studies with cytotoxic anthrapyrazoles. Oncol Rep. 2006 Jun;15(6):1575-80. PubMed PMID: 16685398. 5: Kaye SB, Workman P, Graham MA, Cassidy J, Jodrell D. Pharmacokinetics and early clinical studies of selected new drugs. Cancer Surv. 1993;17:371-96. Review. PubMed PMID: 8137348. 6: Kiraly A, Koffman B, Hacker M, Gunning W, Rasche S, Quinn A. A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity. Clin Immunol. 2011 Dec;141(3):304-16. doi: 10.1016/j.clim.2011.08.009. Epub 2011 Aug 30. PubMed PMID: 21964417. 7: Judson IR. Anthrapyrazoles: true successors to the anthracyclines? Anticancer Drugs. 1991 Jun;2(3):223-31. Review. PubMed PMID: 1802016. 8: Zhang R, Wu X, Yalowich JC, Hasinoff BB. Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents. Bioorg Med Chem. 2011 Dec 1;19(23):7023-32. doi: 10.1016/j.bmc.2011.10.012. Epub 2011 Oct 14. PubMed PMID: 22041173; PubMed Central PMCID: PMC3212645. 9: Fry DW. Biochemical pharmacology of anthracenediones and anthrapyrazoles. Pharmacol Ther. 1991 Oct;52(1):109-25. Review. PubMed PMID: 1666677. 10: D'Incalci M, Capranico G, Giaccone G, Zunino F, Garattini S. DNA topoisomerase inhibitors. Cancer Chemother Biol Response Modif. 1993;14:61-85. Review. PubMed PMID: 8312123. 11: Judson IR. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Semin Oncol. 1992 Dec;19(6):687-94. Review. PubMed PMID: 1462167. 12: Berg SL. Status of new anthrapyrazole and pyrazoloacridine derivatives. Crit Rev Oncol Hematol. 1996 Mar;22(2):79-87. Review. PubMed PMID: 8679102. 13: Sissi C, Palumbo M. Antitumor potential of aza-bioisosterism in anthracenedione-based drugs. Curr Top Med Chem. 2004;4(2):219-30. Review. PubMed PMID: 14754455. 14: Ogawa M, Ariyoshi Y. [New anthracyclines]. Gan To Kagaku Ryoho. 1993 Jan;20(1):27-33. Review. Japanese. PubMed PMID: 8422185. 15: Wang J, Zhao H, Luo Z, Wang Z, Zhang Y, Zhao J. Synthesis and biological activity of anthrapyrazoles derivatives as potential antitumor agents. Med Chem. 2014;10(8):772-7. PubMed PMID: 24773347. 16: Hawkins MJ. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles. Oncology (Williston Park). 1992 Dec;6(12):17-23; discussion 27-30. Review. Erratum in: Oncology (Huntingt) 1993 Mar;7(3):105. PubMed PMID: 1361358. 17: Fiebig HH, Berger DP, Winterhalter BR, Plowman J. In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat Rev. 1990 Sep;17(2-3):109-17. PubMed PMID: 2272027. 18: Chou KM, Paul Krapcho A, Hacker MP. Impact of the basic amine on the biological activity and intracellular distribution of an aza-anthrapyrazole: BBR 3422. Biochem Pharmacol. 2001 Nov 15;62(10):1337-43. PubMed PMID: 11709193. 19: Klohs WD, Steinkampf RW. Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. Cancer Res. 1988 Jun 1;48(11):3025-30. PubMed PMID: 3365692. 20: Chen KX, Gresh N, Pullman B. A theoretical study of the intercalative binding of the anti-tumour drug anthrapyrazole to double-stranded oligonucleotides. Anticancer Drug Des. 1987 Aug;2(1):79-84. PubMed PMID: 3482353.